TZIELD (teplizumab) can give patients more symptom-free time in Stage 2 autoimmune T1D vs placebo, delaying a lifetime of symptom management and insulin therapy1–3
A delay in the onset of stage 3 T1D may provide your patients with:
More insulin-free years4-6
Delaying the social stigma and lifestyle disruptions that come with managing T1D4,5,7
Time for vigilant monitoring of signs and symptoms of DKA6
To reduce the risk of hospitalisation with DKA6
Increased opportunities to learn about glycaemic control8
So your patients can learn how to properly manage their disease9
Real-world experiences of patients treated with TZIELD
An online survey of 47 adults and caregivers of children who received TZIELD revealed:*10
patients felt TZIELD would help slow down T1D
patients felt TZIELD would make managing T1D easier to manage
patients were glad they, or their child, had TZIELD
Get in Touch with Us
Questions? Leave your details and we'll reach out to you at your preferred time.
Get in touchINDICATION: TZIELD is indicated to delay the onset of Stage 3 T1D in adult and paediatric patients 8 years of age and older with Stage 2 T1D.4
*Cross-sectional, observational, online survey of adults and caregivers of children who received TZIELD while participating in the US COMPASS patient support program. Of the 116 individuals invited to take part, 47 responded.10 Patients reported whether they strongly agreed, agreed, felt neutral about, disagreed, or strongly disagreed with statements pertaining to their views and expectations about TZIELD. All statements shown were responded to by all participants and there were no missing data.10
DKA, diabetic ketoacidosis; T1D, Type 1 diabetes.
MAT-XU-2500772 (v3.0) | September 2026